Identification and functional activity of matrix-remodeling associated 5 (MXRA5) in benign hyperplastic prostate

Objective: Benign prostatic hyperplasia (BPH) is a common condition in aging males. The current study aims to identify differentially expressed genes (DEGs) associated with BPH and to elucidate the role of matrix-remodeling associated 5 (MXRA5) protein and mitogen-activated protein kinase (MAPK) signaling pathways in BPH. Results: A total of 198 DEGs and a number of related pathways were identified with MXRA5 being one of the most significantly altered DEGs. MXRA5 was upregulated in BPH samples and localized mostly in stroma. Knockdown of MXRA5 induced stromal cell cycle arrest instead of inhibiting apoptosis. Consistently, MXRA5 overexpression enhanced epithelial cell proliferation. In addition, phosphorylated ERK1/2 and p38, key members of the MAPK family, were strongly decreased with knockdown but increased with overexpression. Conclusion: Our novel data demonstrates that upregulation of MXRA5 in the enlarged prostate could contribute to the development of BPH through increasing cell proliferation via the MAPK pathway. Thus, the MXRA5-MAPK system could be rediscovered as a new therapeutic target for treating BPH. Methods: Microarray analysis and integrated bioinformatics were conducted. The expression and biologic functions of MXRA5 was investigated via RT-PCR, western-blot, immunofluorescence, flow cytometry and MTT assay. Finally, genes involved in regulation of the MAPK pathway were investigated.

[1]  R. Tibshirani,et al.  Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis. , 2019, JCI insight.

[2]  Shaocong Li,et al.  MXRA5 is decreased in preeclampsia and affects trophoblast cell invasion through the MAPK pathway , 2017, Molecular and Cellular Endocrinology.

[3]  M. Sánchez-Niño,et al.  MXRA5 is a TGF‐β1‐regulated human protein with anti‐inflammatory and anti‐fibrotic properties , 2016, Journal of cellular and molecular medicine.

[4]  K. Loughlin,et al.  Benign prostatic hyperplasia: epidemiology, economics and evaluation. , 2015, The Canadian journal of urology.

[5]  M. Oelke,et al.  EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. , 2015, European urology.

[6]  Chawnshang Chang,et al.  Evidence of TGF-β1 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells , 2014, Molecular membrane biology.

[7]  Jai-Sing Yang,et al.  ERK-modulated intrinsic signaling and G(2)/M phase arrest contribute to the induction of apoptotic death by allyl isothiocyanate in MDA-MB-468 human breast adenocarcinoma cells. , 2012, International journal of oncology.

[8]  L. Yao,et al.  Identification of MXRA5 as a novel biomarker in colorectal cancer , 2012, Oncology letters.

[9]  X. Hua,et al.  Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients. , 2012, Carcinogenesis.

[10]  Hamid Hossain,et al.  Cre-Mediated Stress Affects Sirtuin Expression Levels, Peroxisome Biogenesis and Metabolism, Antioxidant and Proinflammatory Signaling Pathways , 2012, PloS one.

[11]  Yilin Zhang,et al.  Microarray-based bioinformatics analysis of osteoblasts on TiO2 nanotube layers. , 2012, Colloids and surfaces. B, Biointerfaces.

[12]  Bin Wu,et al.  Differences in gene expression profiles and carcinogenesis pathways between colon and rectal cancer , 2012, Journal of digestive diseases.

[13]  A. Kozubík,et al.  TGF‐β1‐induced EMT of non‐transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug , 2011, The Prostate.

[14]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[15]  J. Gustafsson,et al.  A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia , 2009, Proceedings of the National Academy of Sciences.

[16]  J. Pouysségur,et al.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition , 2007, Oncogene.

[17]  A. Gabrielsen,et al.  Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. , 2007, Journal of molecular and cellular cardiology.

[18]  J. Hubbell,et al.  Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering , 2005, Nature Biotechnology.

[19]  R. Dhir,et al.  Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Trent,et al.  Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis , 2002, The Prostate.

[21]  T. Habuchi,et al.  Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. , 2000, Cancer research.

[22]  R. Roberts,et al.  Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. , 1999, The Journal of urology.

[23]  Colombel,et al.  Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. , 1998, British journal of urology.

[24]  A. Hoffman,et al.  Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. , 1997, The Journal of clinical endocrinology and metabolism.

[25]  H. Lepor,et al.  Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. , 1997, The Journal of urology.

[26]  N. Kyprianou,et al.  Apoptotic versus proliferative activities in human benign prostatic hyperplasia. , 1996, Human pathology.

[27]  D. Neal,et al.  Peptide growth factors in the prostate as mediators of stromal epithelial interaction. , 1996, British journal of urology.

[28]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[29]  S. Goodman,et al.  Cellular responses to extracellular matrix. , 1992, Kidney international.

[30]  P. V. van Helden,et al.  Hypomethylation of DNA in pathological conditions of the human prostate. , 1987, Cancer research.

[31]  D. Gospodarowicz,et al.  Determination of cellular shape by the extracellular matrix and its correlation with the control of cellular growth. , 1978, Cancer research.

[32]  M. Gillies,et al.  Genomic analysis using Affymetrix standard microarray genechips (169 format) in degenerate murine retina. , 2015, Methods in molecular biology.

[33]  W. Kwapong,et al.  Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers. , 2015, Cancer biomarkers : section A of Disease markers.

[34]  T. Tan,et al.  Mitogen-activated protein kinases in cell-cycle control , 2007, Cell Biochemistry and Biophysics.

[35]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[36]  H. Lepor,et al.  The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle , 1993, The Prostate.

[37]  J. Mcconnell.  Medical management of benign prostatic hyperplasia with androgen suppression , 1990, The Prostate. Supplement.

[38]  E. Schneider,et al.  DNA alterations in prostatic adenocarcinoma and benign prostatic hyperplasia: detection by DNA fingerprint analyses. , 1990, Mutation research.